Get started
Author

Naoko Okura

Observed name: Okura, Naoko
OpenAlex ID: A5113936960
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR -Mutated Non–Small Cell Lung Cancer
2020 · Naoko Okura, Naoya Nishioka, et al. · Clinical Cancer Research · 123
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
2019 · Naoya Nishioka, Junji Uchino, et al. · Journal of Clinical Medicine · 93
PDF
Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
2020 · Yuki Katayama, Tadaaki Yamada, et al. · Scientific Reports · 39
PDF
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
2020 · Naoko Okura, Mai Asano, et al. · Journal of Clinical Medicine · 32
PDF
Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
2021 · Ryo Sawada, Yohei Matsui, et al. · Internal Medicine · 14
PDF
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
2022 · Yuki Katayama, Tadaaki Yamada, et al. · Cancer Medicine · 11
PDF
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
2019 · Akihiro Yoshimura, Tadaaki Yamada, et al. · Cancers · 11
PDF
Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report
2018 · Naoya Nishioka, Tadaaki Yamada, et al. · Respiratory Medicine Case Reports · 8
PDF
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
2018 · Akihiro Yoshimura, Tadaaki Yamada, et al. · BMC Cancer · 3
PDF
Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma
2018 · Naoya Nishioka, Yoshiko Kaneko, et al. · Respirology Case Reports · 3
PDF
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study
2024 · Akihiro Yoshimura, Takayuki Takeda, et al. · Frontiers in Oncology · 2
PDF
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study
2023 · Keiko Tanimura, Takayuki Takeda, et al. · Cancers · 2
PDF
Figure S1-S10 from ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
2023 · Naoko Okura, Naoya Nishioka, et al.
Table S1, S2 from ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
2023 · Naoko Okura, Naoya Nishioka, et al.
Figure S1-S10 from ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
2023 · Naoko Okura, Naoya Nishioka, et al.
Table S1, S2 from ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
2023 · Naoko Okura, Naoya Nishioka, et al.
Data from ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
2023 · Naoko Okura, Naoya Nishioka, et al.
Data from ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer
2023 · Naoko Okura, Naoya Nishioka, et al.
ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated NSCLC
2020 · Naoko Okura, Hirokazu Taniguchi, et al. · 日本癌学会学術総会抄録集(Web)
Abstract 4899: The impact of the EGFR -T790M mutation detection by re-biopsy in EGFR mutant NSCLC patients in the retrospective analysis
2019 · Akihiro Yoshimura, Tadaaki Yamada, et al. · Cancer Research
Abstract 4899: The impact of theEGFR-T790M mutation detection by re-biopsy in EGFR mutant NSCLC patients in the retrospective analysis
2019 · Akihiro Yoshimura, Tadaaki Yamada, et al. · Clinical Research (Excluding Clinical Trials)
Works count: 23
Citation count: 341
H-index: 8
I10-index: 7
Year
Topic
Type